BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 11, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 12/8 cls
Acambis (LSE:ACM; ACAM) Bridgewell Shawn Manning New Buy 3% 104p
Manning set a 146p target. He expects approval or an approvable letter for ACM's BLA for ACAM2000 smallpox vaccine by its Feb. 14, 2007, PDUFA date. Manning also expects the company to launch its ChimeriVax-JE vaccine in 2008 and estimates it will generate annual revenues of £19M ($37.6M) by 2011.
Achillion (ACHN) Cowen Joshua Schimmer New Market outperform 15% $17.52
JMP Securities Adam Cutler New Market outperform
Schimmer said ACHN's elvucitabine HIV compound has a "relatively low development risk" and expects Phase III testing to begin next year.
Cutler set a $19 target. He believes elvucitabine, in Phase II for HIV, has a longer half-life than approved nucleoside reverse transcriptase inhibitors. He expects Phase II data in 1H07.

Read the full 993 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >